|
02 Jun 2019 |
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
|
|
02 Jun 2019 |
IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer
|
|
01 Jun 2019 |
CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting
|
|
01 Jun 2019 |
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
|
|
01 Jun 2019 |
Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma
|
|
01 Jun 2019 |
Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting
|
|
01 Jun 2019 |
Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting
|
|
01 Jun 2019 |
ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
|
|
31 May 2019 |
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
|
|
31 May 2019 |
U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
|
|
31 May 2019 |
Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
|
|
31 May 2019 |
GT Biopharma GTB-1550 Clinical Development Update
|
|
30 May 2019 |
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
|
|
30 May 2019 |
Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH
|
|
29 May 2019 |
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer’s Disease with Selectivity for the Neurotoxic Form of Tau
|
|
28 May 2019 |
European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review
|
|
24 May 2019 |
Immunovant Initiates Dosing in ASCEND-GO 1, a Phase 2a Trial of IMVT-1401 in Patients with Graves' Ophthalmopathy (GO)
|
|
23 May 2019 |
Alteogen Inc. gets IND approval for a clinical study in Korea for Eylea Biosimilar (ALT-L9)
|
|
22 May 2019 |
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
|
|
22 May 2019 |
Entyvio® (vedolizumab) Approved in Japan for the Treatment of Patients with Moderately to Severely Active Crohn's Disease
|
|
22 May 2019 |
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
|
|
21 May 2019 |
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
|
|
21 May 2019 |
Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation
|
|
21 May 2019 |
Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
|
|
18 May 2019 |
Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
|
